Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LGMN | Q99538 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25810008 | 0.91 | HTR1A (0.44) | HRH4MAPTMAPK1HTTALDH1A1 | |
| SCHEMBL31026002 | 0.89 | KDM4E (0.47) | MAPTALDH1A1PTPN2GAAKDM4E | |
| SCHEMBL30492912 | 0.89 | KDM4E (0.47) | MAPTALDH1A1PTPN2GAAKDM4E | |
| SCHEMBL30492840 | 0.87 | OGA (0.43) | MAPTMAPK1HTTALDH1A1PTPN2 | |
| SCHEMBL31025983 | 0.87 | OGA (0.43) | MAPTMAPK1HTTALDH1A1PTPN2 | |
| SCHEMBL31025977 | 0.87 | LGMN (0.51) | MAPTMAPK1HTTALDH1A1GAA | |
| SCHEMBL25810428 | 0.87 | CHRNA7 (0.43) | MAPTMAPK1HTTALDH1A1PTPN2 | |
| SCHEMBL30492856 | 0.87 | LGMN (0.51) | MAPTMAPK1HTTALDH1A1GAA | |
| SCHEMBL30492874 | 0.87 | CHRNA7 (0.43) | MAPTMAPK1HTTALDH1A1PTPN2 | |
| SCHEMBL31025971 | 0.86 | LGMN (0.43) | MAPTMAPK1HTTALDH1A1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074902-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) | 2025-03-06 | — | — | US | disclosed |
| WO-2025002040-A1 | CRYSTAL FORM OR SALT OF BICYCLIC HETEROARYL AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海京新生物医药有限公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4458824-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | Shanghai Jingxin Biomedical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118488951-A | Fused bicyclic heteroaryl amide compounds as inhibitors of protein aggregation | 上海京新生物医药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074902-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | HTT, PARK7, FUS | HRH4 2267/4885MAPT 9/4885MAPK1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.